Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sanvia LLC currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit, representing a very narrow prosecution footprint. The examiner assigned to this case is AZPURU, CARLOS A, who handles the 1 pending office action. With only 1 distinct examiner involved, the company's current patent strategy is highly centralized, focusing all resources on a single point of contact at the patent office.
The presence of 1 distinct art unit suggests the technology is currently focused on a specific sub-discipline within the broader biotechnology field. This limited scope allows for a highly targeted response strategy for the single pending action, as there are no conflicting examiner requirements to balance. Practitioners can dedicate their efforts to understanding the specific prior art and patentability thresholds favored by AZPURU, CARLOS A. This singular focus reduces the complexity often found in larger, more distributed portfolios.
Because there is only 1 pending office action, the immediate goal for Sanvia LLC is likely to secure an allowance or move to a favorable final disposition. The involvement of a single art unit means that the technical expertise required for this prosecution is highly specialized. The company benefits from a clear and direct line of communication with the assigned examiner, which can often lead to more efficient resolutions than portfolios spread across multiple units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707160 | BIOCOMPATIBLE COMPOSITE MATERIAL AND METHOD OF MAKING THE SAME | AZPURU, CARLOS A | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707160 | BIOCOMPATIBLE COMPOSITE MATERIAL AND METHOD OF MAKING THE SAME | AZPURU, CARLOS A | 27d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707160 | BIOCOMPATIBLE COMPOSITE MATERIAL AND METHOD OF MAKING THE SAME | AZPURU, CARLOS A | 1617 | §103Other | Non-Final OA | 27d | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial